| Market Capitalization (Millions $) |
251 |
| Shares
Outstanding (Millions) |
64 |
| Employees |
293 |
| Revenues (TTM) (Millions $) |
168 |
| Net Income (TTM) (Millions $) |
-15 |
| Cash Flow (TTM) (Millions $) |
-64 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Macrogenics Inc. is a clinical-stage biopharmaceutical company headquartered in Rockville, Maryland, with additional locations in Virginia and California. The company's mission is to discover and develop innovative therapeutics to address unmet needs in cancer and autoimmune diseases.
Macrogenics Inc. was founded in 2000 by Scott Koenig, who currently serves as the company's President and CEO. The company has since grown to employ approximately 300 people and has raised over $1 billion in funding.
Macrogenics Inc.'s proprietary technology platform is called Dual-Affinity Re-Targeting, or DART, which allows for the development of bi-specific antibodies that can target two different receptors simultaneously. The company's pipeline consists of several bi-specific antibodies in various stages of clinical development.
In oncology, Macrogenics Inc. is focused on developing bi-specific antibodies to target specific cancer cells and to engage and activate immune cells to combat the cancer. Their lead drug candidate in this area is margetuximab, a bi-specific antibody designed to target HER2-expressing breast cancer cells.
In autoimmune diseases, the company is developing bi-specific antibodies that target receptors involved in inflammatory and immune responses. Their lead drug candidate in this area is teplizumab, a bi-specific antibody designed to target T cells and modulate the immune response in type 1 diabetes.
Macrogenics Inc. has established partnerships with several pharmaceutical companies, including Eli Lilly, Incyte, and Janssen Biotech. These partnerships provide the company with additional funding and resources to advance their drug development programs.
In summary, Macrogenics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancer and autoimmune diseases using its proprietary DART technology platform. The company has established partnerships with several pharmaceutical companies and has a pipeline of bi-specific antibodies in various stages of clinical development.
Company Address: 9704 Medical Center Drive Rockville 20850 MD
Company Phone Number: 251-5172 Stock Exchange / Ticker: NASDAQ MGNX
|
79.37 %